The research team led by scientists from Harvard and Oxford has developed a simple blood test that may predict which people with hypertrophic cardiomyopathy (HCM) face the greatest risk of serious complications. In a study of 700 patients, higher levels of the heart-derived protein N-terminal pro-B-type natriuretic peptide (NT-pro-BNP) were linked with poorer blood flow, more scar tissue and structural changes that can presage atrial fibrillation or heart failure. The finding suggests a blood biomarker could help clinicians target monitoring and interventions to those most likely to benefit, while sparing low-risk patients unnecessary treatments. The study was funded in part by the British Heart Foundation and reported by teams at major research centres in 2025.
Key Takeaways
- Researchers measured NT-pro-BNP in 700 people diagnosed with hypertrophic cardiomyopathy (HCM) to test its prognostic value.
- Patients with the highest NT-pro-BNP levels showed signs of poorer myocardial blood flow, more cardiac scar tissue and structural changes linked to arrhythmia and heart failure.
- The test could stratify patients into higher and lower risk groups, enabling closer surveillance or earlier treatment for those at greatest risk.
- Study leadership included Prof Carolyn Ho (Harvard) and collaborators at Oxford; the British Heart Foundation provided funding support.
- Patient testimony highlights the psychological burden of uncertainty in HCM and the potential value of a simple risk marker for families.
- Authors caution that further validation and guideline integration are needed before routine clinical use.
Background
Hypertrophic cardiomyopathy is the world’s most common inherited heart muscle disorder, affecting millions globally and usually caused by changes in one or more genes passed down in families. Clinical expression varies widely: some people remain asymptomatic or mildly symptomatic for decades, while others develop progressive symptoms, heart failure, dangerous arrhythmias or sudden cardiac arrest. There is currently no cure for HCM; management focuses on reducing symptoms, preventing complications and in some cases inserting devices or performing procedures. A major clinical challenge has been reliably identifying which gene-positive or diagnosed patients will go on to experience severe outcomes, creating uncertainty for patients and clinicians about when to escalate care.
Conventional risk assessment combines imaging, family history and symptom evaluation, but it can still leave substantial prognostic ambiguity. Biomarkers measured from blood offer a minimally invasive route to capture ongoing physiological stress in the heart and could complement imaging-based assessments. Prior work has associated natriuretic peptides with cardiac strain in other conditions, but large, disease-specific cohorts for HCM have been limited until now. The new study addresses that gap by testing NT-pro-BNP across a sizeable, well-characterised HCM cohort.
Main Event
The multicentre study collected blood samples and clinical data from 700 people with HCM and measured circulating NT-pro-BNP concentrations. NT-pro-BNP is a peptide released by cardiac muscle in response to increased wall stress and impaired filling; elevated levels are an established marker of cardiac strain in heart failure and other disorders. Investigators analysed associations between NT-pro-BNP levels and objective markers of heart structure and function, including measures of blood flow and the presence of myocardial scar on imaging.
Results showed that participants with the highest NT-pro-BNP concentrations had demonstrably worse perfusion measures, greater scar burden on imaging and structural abnormalities that have been linked to atrial fibrillation and progression to heart failure. The pattern persisted after adjusting for common clinical variables, supporting the peptide’s independent association with adverse cardiac features in HCM. Authors emphasise the test is not presented as diagnostic of HCM but as a prognostic adjunct to identify patients at elevated risk of complications.
Based on these findings, the team suggests a pathway in which NT-pro-BNP measurement helps triage patients: those with high levels would receive intensified surveillance, consideration for earlier therapeutic interventions, or prioritisation for trials of novel treatments, while low-level patients might avoid unnecessary invasive procedures. The investigators noted that routine implementation would require standardised thresholds and prospective outcome studies to confirm that biomarker-guided care improves hard endpoints.
Analysis & Implications
If validated in further studies, a single blood biomarker that flags higher risk in HCM could materially change clinical pathways by enabling risk-stratified care. For clinicians, NT-pro-BNP could add an objective, repeatable data point alongside echocardiography and MRI to refine decisions about device therapy, antiarrhythmic strategies and timing of interventions. For health systems, targeted monitoring and treatment could concentrate resources on those most likely to benefit, potentially improving outcomes and optimising costs, though formal health-economic appraisal is required.
For patients and families, a prognostic blood test could reduce long-term uncertainty and inform life decisions such as work, family planning and exercise. However, there are ethical and practical considerations: communicating probabilistic risk requires careful counselling, and false reassurance or overinterpretation of a single biomarker must be avoided. Integration into practice will also demand that laboratories can reliably measure NT-pro-BNP with harmonised assays and that clinicians agree on action thresholds.
At the research level, the finding points to biological pathways linking myocardial stress, scar formation and arrhythmia risk in genetically mediated cardiomyopathy. That mechanistic insight could spur development of targeted therapies aimed at reducing myocardial stress or preventing fibrotic remodelling. Nevertheless, the step from association to practice-changing intervention requires prospective trials showing that biomarker-based strategies lower rates of heart failure, arrhythmia or sudden cardiac death.
Comparison & Data
| Feature | High NT-pro-BNP | Low NT-pro-BNP |
|---|---|---|
| Cohort size | 700 participants (overall) | |
| Myocardial scar | More frequently observed | Less frequently observed |
| Perfusion/blood flow | Evidence of poorer flow | Relatively preserved |
| Clinical implication | Higher risk of arrhythmia/heart failure | Lower short-term risk profile |
The table summarises qualitative relationships reported in the cohort: elevated NT-pro-BNP correlated with markers of worse myocardial structure and function. Because the published report does not provide universal numeric cut-offs for risk categories applicable to all settings, clinicians and laboratories will need standardised protocols and validation studies before adopting a strict threshold-based workflow.
Reactions & Quotes
Study leaders and funders emphasised both the potential patient benefit and the need for further research. The team framed the result as an important step toward personalised risk stratification in HCM.
“This approach could help target the right therapies to the right patients at the right time,”
Prof Carolyn Ho, Harvard Medical School (study leader)
The British Heart Foundation described the work as promising for global patient care, while noting that follow-up research is required to translate biomarker signals into clinical practice.
“Measuring circulating proteins could help predict how the heart is functioning and future risk of complications,”
Prof Bryan Williams, British Heart Foundation (chief scientific and medical officer)
Patients who live with HCM welcomed the prospect of less uncertainty and earlier, tailored interventions if high-risk individuals can be identified reliably.
“A simple blood test that could identify future risks earlier would take away so much of that anxiety,”
Lara Johnson, patient from Southampton
Unconfirmed
- Exact NT-pro-BNP thresholds that define low, intermediate and high risk in HCM remain to be prospectively validated.
- Whether biomarker-guided management will reduce deaths, heart failure admissions or sudden cardiac arrest has not yet been proven in randomised outcome trials.
- Generalisability across all genetic subtypes, ages and ethnic groups requires additional study and cannot be assumed from the current cohort.
Bottom Line
The study offers compelling evidence that a widely available blood marker, NT-pro-BNP, correlates with features of worse heart structure and function in people with HCM and could be used to stratify risk. If subsequent prospective studies validate these findings and define actionable thresholds, clinicians may be able to personalise monitoring and treatment more precisely, focusing resources on those most likely to benefit.
However, routine clinical adoption hinges on standardised assays, guideline endorsement and trials showing improved clinical outcomes from biomarker-driven care pathways. For patients and families living with inherited cardiomyopathy, the prospect of reduced uncertainty and more tailored care is promising, but cautious, evidence-based implementation will be key to real benefit.
Sources
- The Guardian — media report summarising the study and patient perspectives (press coverage).
- British Heart Foundation — charity and funder (official organisation supporting cardiovascular research).
- Harvard Medical School — academic institution (research centre affiliated with study leadership).